NASDAQ: COYA - Coya Therapeutics, Inc.

Rentabilität für sechs Monate: +15.69%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Coya Therapeutics, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Coya Therapeutics, Inc.

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis.

weitere details
The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2022-12-29
ISIN US22407B1089
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.coyatherapeutics.com
Цена ао 6
Preisänderung pro Tag: +5.2% (6.73)
Preisänderung pro Woche: +10.45% (6.41)
Preisänderung pro Monat: +21.03% (5.85)
Preisänderung über 3 Monate: +8.59% (6.52)
Preisänderung über sechs Monate: +15.69% (6.12)
Preisänderung pro Jahr: -28.84% (9.95)
Preisänderung über 3 Jahre: 0% (7.08)
Preisänderung über 5 Jahre: 0% (7.08)
Preisänderung über 10 Jahre: 0% (7.08)
Preisänderung seit Jahresbeginn: +21.86% (5.81)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 12.11 1
P/BV 2.04 7
P/E 0 0
EV/EBITDA -5.46 0
Gesamt: 4.75

Effizienz

Name Bedeutung Grad
ROA, % -19.35 0
ROE, % -22.41 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -1.77 10
Gesamt: 8.4

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 0 0
Rentabilität Ebitda, % 1033.24 10
Rentabilität EPS, % 938.19 10
Gesamt: 8
Weitere Details

Institutionen Volumen Aktie, %
Greenlight Capital, Inc. 1274026 8.72
AIGH Capital Management LLC 1031977 7.07
CM Management, LLC 100000 0.68
Vanguard Group Inc 97152 0.67
Worth Venture Partners, LLC 92667 0.63
Geode Capital Management, LLC 92465 0.63
Prelude Capital Management LLC 35770 0.24
Blackrock Inc. 21775 0.15
Potomac Capital Management, Inc. 21101 0.14
Citadel Advisors Llc 16592 0.11

ETF Aktie, % Rentabilität für das Jahr, % Dividenden, %
iShares Micro-Cap ETF 0.02048 17.09 1.54048



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. Howard Berman Ph.D. Chairman & CEO 833.75k 1974 (51 Jahr)
Mr. David S. Snyder CFO & COO 610.94k 1960 (65 Jahre)
Dr. Fred Grossman D.O., FAPA President & Chief Medical Officer 610.63k 1962 (63 Jahr)
Dr. Gregory MacMichael Ph.D. Chief Technical Officer N/A 1956 (69 Jahre)
Dr. Michelle Frazier Ph.D. Senior Vice President of Regulatory Affairs N/A
Mr. Aaron Thome Ph.D. Head of Neuroinflammation Platform N/A
Dr. Arun Swaminathan Ph.D. Chief Business Development Officer N/A

Adresse: United States, Houston. TX, 5850 San Felipe Street - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.coyatherapeutics.com